← Back to Search
Cardiac Safety Of Adjuvant Pegylated Liposomal Doxorubicin With Concurrent Trastuzumab: A Randomized Phase II Trial.
D. Rayson, T. Suter, C. Jackisch, S. Van Der Vegt, B. Bermejo, J. van den Bosch, G. L. Vivanco, A. M. van Gent, H. Wildiers, A. Torres, L. Provencher, M. Temizkan, J. Chirgwin, J. Canon, G. Ferrandina, S. Srinivasan, L. Zhang, D. Richel
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
BACKGROUND The cardiac safety of trastuzumab concurrent with pegylated liposomal doxorubicin (PLD) in an adjuvant breast cancer treatment regimen is unknown. PATIENTS AND METHODS Women with resected node-positive or intermediate-risk node-negative HER2 overexpressing breast cancer and baseline left ventricular ejection fraction (LVEF)≥55% were randomized (1:2) to doxorubicin 60 mg/m2 (A)+cyclophosphamide 600 mg/m2 (C) every 21 days (q21d) for four cycles or PLD 35 mg/m2+C q21d+trastuzumab 2 mg/kg weekly (H) for 12 weeks. Both groups then received paclitaxel (Taxol, T) 80 mg/m2 with H for 12 weeks followed by H to complete 1 year. The primary end point was cardiac event rate or inability to administer 1 year of trastuzumab. RESULTS Of 181 randomized patients, 179 underwent cardiac analysis. The incidence of cardiac toxicity or inability to administer trastuzumab due to cardiotoxicity was 18.6% [n=11; 95% confidence interval (CI) 9.7% to 30.9%] with A+C→T+H and 4.2% (n=5; 95% CI 1.4% to 9.5%) with PLD+C+H→T+H (P=0.0036). All events, except one, were asymptomatic systolic dysfunction or mildly symptomatic heart failure. Mean absolute LVEF reduction at cycle 8 was greater with doxorubicin (5.6% versus 2.1%; P=0.0014). CONCLUSION PLD+C+H→T+H is feasible and results in lower early cardiotoxicity rates compared with A+C→T+H.
This paper references
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group Trial E3198
A. Wolff (2010)
Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines.
D. M. Collins (2012)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart (2005)
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
J. Bartlett (2010)
Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
D. Rayson (2008)
In the Netherlands
H. V. Gelder (1961)
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
H. Joensuu (2009)
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
M. Procter (2010)
Dublin City University, Dublin; 2 Molecular Therapeutics for Cancer Ireland (MTCI) and UCD School of Medicine and Medical Science
Meeting highlights: international expert consensus on the primary treatment of early breast cancer
A Goldhirsch (2005)
Herceptin Package Insert Welwyn Garden City
Limited Roche Registration (2005)
erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
S. Paik (1998)
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
A. Buzdar (2005)
The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin.
G. Berry (1998)
Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
E. Andreopoulou (2007)
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial
E. Stickeler (2008)
Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2
iT. Safra (2005)
Academic medical center.
Heyssel Rm (1985)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
K. Pritchard (2006)
Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
M. Trudeau (2009)
Results of Chemotherapy Alone, with Sequential or Concurrent Addition of 52 Weeks of Trastuzumab in the NCCTG N9831 HER2-Positive Adjuvant Breast Cancer Trial.
E. Perez (2009)
Cardiac profiles of liposomal anthracyclines
M. Theodoulou (2004)
D M Collins
Hospital Provincial Hospital de Cruces Annals of Oncology
Antonio Anton Torres (2011)
Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
C. Christodoulou (2009)
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
M. Ewer (2005)
Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
A. Goldhirsch (2005)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials.
A. Gennari (2008)
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15.
S. Paik (2000)
Dublin; 4 Molecular Therapeutics for Cancer Ireland (MTCI) and Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital
Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC→TH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in Her2neu Positive Early Breast Cancer Patients: BCIRG 006 Study.
D. Slamon (2009)
This paper is referenced by
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
Elena Geretti (2015)
Antitumour Anthracyclines: Progress and Perspectives
M. Martins-Teixeira (2020)
Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: focus on liposomes.
E. Tahover (2015)
Enhancing Cisplatin Delivery and Anti-tumor Efficacy Using Hyperthermia
Chelsea D. Landon (2013)
Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview
P. Menna (2017)
Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer
A. Chang (2018)
The Future of Chemotherapy in the Era of Personalized Medicine
Maria Vittoria Dieci (2012)
Surviving Cancer without a Broken Heart
O. Caspi (2019)
Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value
K. Skubitz (2017)
Trastuzumab cardiotoxicity: from clinical trials to experimental studies
B. Németh (2017)
Current status of nanomedicine in the chemotherapy of breast cancer
A. I. Fraguas-Sánchez (2019)
Potential environmental implications of nano-enabled medical applications: critical review.
Indrani Mahapatra (2013)
The role of anthracyclines in the treatment of early breast cancer
J. Greene (2015)
Trastuzumab Cardiac Toxicity: A Problem we Put our Heart Into
G. Bregni (2016)
Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer
S. Mantarro (2015)
Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study
K. Rau (2015)
Cardioprotection in the Modern Era of Cancer Chemotherapy
A. Godishala (2018)
Cardiac risk in the treatment of breast cancer: assessment and management
A. Valachis (2015)
Biotoxicity of Chemotherapy
C. Fung (2014)
Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.
X. He (2012)
Targeted Therapies for HER2-positive Breast Cancer
M. V. Dieci (2015)
Pegylated Liposomal Doxorubicin: A Guide to Its Use in Various Malignancies
K. Lyseng-Williamson (2013)
Onco-Cardiology for Breast Cancer
O. Soran (2016)
The use of unequal randomisation in clinical trials--An update.
E. Peckham (2015)
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
Anthracycline Cardiotoxicity: It Is Possible to Teach an Old Dog Some New Tricks.
Jose Alvarez-Cardona (2019)
New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.
Alberto A. Gabizon (2016)
The concomitant management of cancer therapy and cardiac therapy.
E. Salvatorelli (2015)
Principles of a risk evaluation and mitigation strategy (REMS) for breast cancer patients receiving potentially cardiotoxic adjuvant treatments
Sherif Ahmed (2016)